Ticker: XFOR

X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) has recently reported its financial results for the quarter ending March 31, 2025. The company is primarily focused on the development and commercialization of novel therapeutics for rare diseases, with its lead product, XOLREMDI, recently approved for the ...